Sosei Group Corporation (SOLTF)

- Dosing of first subject in clinical trial by Pfizer triggers $5 million payment to Sosei Heptares - Clinical development candidate is an oral, small molecule modulator of an undisclosed G protein-coupled receptor (GPCR) target TOKYO and LONDON, Dec. 23, 2019 /PR... Read this article on SOLTF https://marketwirenews.com/news-releases/sosei-heptares-announces-the-first-phase-i-clinical--6093181360989372.html?i=y